Dendreon Corp. (DNDN) Catches Eye: Stock Up 8% - Tale of the Tape

Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise nearly 8% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company as the stock is now down about 13.16% in the past one-month time frame.

The company has seen 10 positive estimate revisions in the past month, while its Zacks Consensus Estimate, which is pegged at a loss, narrowed over the same period, suggesting that more solid trading could be ahead for Dendreon. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Dendreon Corp currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Other attractive players in the healthcare industry include Gilead Sciences Inc. (NASDAQ: GILD), Myriad Genetics Inc. (NASDAQ: MYGN) and ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), all carrying a Zacks Rank #1 (Strong Buy)

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ANI PHARMACEUT (NASDAQ: ANIP): Free Stock Analysis Report
 
DENDREON CORP (NASDAQ: DNDN): Free Stock Analysis Report
 
GILEAD SCIENCES (NASDAQ: GILD): Free Stock Analysis Report
 
MYRIAD GENETICS (NASDAQ: MYGN): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research